Dedicated to ensuring the success of the life science industry in the state of Connecticut

The BioCT Leadership and Board of Directors brings industry expertise, advice, and support to the Connecticut life science community. This team looks forward to serving as mentors and advisors to our members.

BioCT Leadership Biographies

Jodie Gillon
President & CEO,
BioCT

Jodie Gillon brings over 25 years of experience in large pharma & biotech having started her career in advocacy and hospitals, in the US and abroad. With vast expertise leading key functions, she is sought after as an advisor to Incubators and Innovation Centers, and as a consultant for biotech, AI, RWE, digital health, and non profit organizations.

Jodie most recently served as the SVP of Corporate Affairs and Patient Advocacy building out the Patient, Medical, and Corporate Affairs functions at Peptilogics, a Phase I and Machine Learning start up. She previously served as the Chief Patient Officer and Head of Clinical Affairs Affairs at Abeona Therapeutics, a cell and gene therapy company. Prior to joining Abeona, Jodie cumulatively spent over a decade with Pfizer as the Global Medical Lead, Patient Engagement, for the Rare Diseases Business Unit and the Director, Medical Communications, within the Chief Medical Office.  Prior to Pfizer, Jodie was the Head of Patient Advocacy and Professional Affairs with Achillion Pharmaceuticals where she led Policy, Alliances, Patient Engagement, Contributions/Grants, Compassionate Use, Medical Information, Medica Communications, Field Medical, and External Affairs. Previously she served as the Head of the Chief Medical Office (CMO) of AstraZeneca, where she managed Patient Engagement, Compassionate Use, Trial and Payment Transparency, Meetings and Events, an HCP Engagement Center, Companywide policy, External contributions, Alliances, and Crisis management. Jodie held additional roles as the Global Communications lead at Novartis, Director of Medical Education for Oridion Medical and as a Health Economist with the Israeli Center for Disease Control and Ministry of Health.

She holds a Master’s of Public Health with a dual degree in Health Economics and Epidemiology from Hebrew University in Jerusalem and a BSFS from Georgetown’s School of Foreign Service. She currently serves on several industry wide Boards and Committees, has published and spoken externally across a wide variety of topics and mentors students and female professionals across our industry. While a native New Yorker, Jodie fell in love with New Haven while at Achillion and is proud to call Connecticut her permanent home for three years now.  She is eager to contribute to the budding ecosystem here and welcomes you to connect with her.

Stanley Choy, M.B.A.
Co-Chair & Treasurer,
Bioscience Entrepreneur

Mr. Choy is an accomplished executive and entrepreneur with over 30 years of cross-functional experience in the healthcare, biotechnology and professional services industries. He is the co-founder of SHY Therapeutics and provides financial and advisory services to early stage, start-up companies. Currently, Mr. Choy is the Chief Financial Officer for Alphina Therapeutics, Inc, and is the Chief Operating Officer for HLK Phamacin, both biotechnology start-up companies.

Earlier in his career, Mr. Choy served as the Vice President, Finance and Administration at Kolltan Pharmaceutics; a Yale affiliated spin-out. Prior to joining Kolltan, Mr. Choy was the Chief Financial Officer for a leading New York/Boston based law firm and was the Controller for Shearman & Sterling. During his tenure at Pfizer, Mr. Choy held several finance positions including finance director of business planning for the Consumer Health Care Division (acquired by Johnson & Johnson), finance director of the Asia & Latin America Region for the Animal Health Care Division (a.k.a., Zoetis, Inc.), and finance director of the US and Asia Region for the Corporate Finance and Treasurer’s Division. He was also instrumental in the integration of the Warner Lambert and Pharmacia acquisitions. Mr. Choy started his career with Arthur Andersen and Company.

Mr. Choy serves as the director and co-chairman of BioCT, the bioscience industry association for the state of Connecticut. He is on the Advisory Board to the BioCT Innovation Commons, a biotechnology start-up incubator in northeastern Connecticut.

Paul Hughes, J.D.
Secretary,
Partner, Wiggin and Dana, LLP

Paul Hughes is a wiggin(x) co-founder and partner, co-chair of Wiggin’s ECVC practice group, partner in corporate and health care departments, and former managing partner of the firm. Paul brings the perspective of a strategic counselor as well as a successful operator. Leveraging three decades of experience, he has been in the middle of some of the world’s most important business transformations, including the digital revolution, the birth and initial boom of the biotech industry, and the advent of managed health care. Paul loves interacting with entrepreneurs tackling big problems and transforming the way we live, and he brings practical solutions to the problems they face.

As such, Paul has broad experience representing venture capital investors as well as advising and operating both emerging and mature companies in industries including software, life sciences, energy, communications, health care, specialty manufacturing, and fintech.

Advising businesses throughout their life cycles on the full range of corporate issues as outside general counsel, Paul focuses on entity formation, obtaining and structuring financing, mergers and acquisitions, intellectual property transactions, divestitures, spin-offs, joint ventures, and strategic alliances.

Outside of the law, Paul enjoys watching the Boston Bruins, racing sailboats, playing golf, and spending time with his wife, their three adult children, and their two black lab rescue dogs.

David I. Scheer, M.S.
Co-Chair,
President, Scheer and Company

Since 1981, David Scheer has led Scheer & Company, Inc., renowned for its successful track record in building and advising life sciences companies. His expertise stems from a decade-long affiliation with Oak Investment Partners, specifically their Health Care Investing Team. Currently, he chairs the boards of four private firms, including BiologicsMD and Adela, Inc., and has co-founded and served on the boards of various others, such as Achillion Pharmaceuticals, Viropharma, and OraPharma.

In his advisory role, Scheer excels in portfolio strategy and diverse corporate transactions, including startups, partnerships, M&A, and IPOs. He has been a senior advisor to CEOs at institutions like the Hospital for Sick Children and the University Health Network in Toronto, focusing on research commercialization. He actively supports startups based on intellectual property from esteemed institutions, including Yale, Children’s Hospital Boston, and the University of Pennsylvania. Additionally, he holds leadership roles in organizations such as BioCT and the Soderstrom Scholars Fund and serves on advisory committees for global health initiatives and medical schools. With a background in biochemistry from Harvard College and an M.S. in Cell, Molecular, and Developmental Biology from Yale University, Mr. Scheer combines academic knowledge with practical experience to make impactful contributions to the life sciences industry and beyond.

BioCT Board of Directors

Mark Adams, Ph.D.
Interim Scientific Director and Professor,
The Jackson Laboratory for Genomic Medicine

Dr. Adams is the Interim Scientific Director at The Jackson Laboratory for Genomic Medicine. He leads the clinical and research genomics services that provide access to next-generation sequencing platforms for researchers and patients.  In a previous role, Dr. Adams was the Scientific Director and Professor at the J. Craig Venter Institute, where he directed programs that characterized genomic changes in the evolution of antibiotic resistance in hospital-acquired infections.

Dr. Adams is best known for being a co-founder of The Institute for Genomic Research and Celera Genomics, where he led the DNA sequencing and genome annotation groups responsible for sequencing of the initial human, mouse, and Drosophila genomes.

He has a BA in Chemistry from Warren Wilson College and a PhD in Biological Chemistry from the University of Michigan.


Abhijit (Jit) Banerjee, Ph.D., M.B.A.
Associate Vice President, Innovation & Entrepreneurship,
University of Connecticut

Reporting to the Vice President for Research, Innovation and Entrepreneurship, Dr. Banerjee supports UConn’s continued growth as an economic driver for the state of Connecticut by helping to set an agenda that defines the University’s program in technology commercialization. He is responsible for all aspects of the University’s technology commercialization activities, including patenting, licensing, venture development, and UConn’s business incubator, the Technology Incubation Program (TIP).


Ranjit Bindra, M.D., Ph.D.
Harvey and Kate Cushing Professor of Therapeutic Radiology,
Yale

Dr. Ranjit Bindra is a physician-scientist at the Yale School of Medicine, the Harvey and Kate Cushing Professor of Therapeutic Radiology, and the Scientific Director of the Yale Brain Tumor Center. Clinically, he treats adult and pediatric primary CNS cancers, as well as brain metastases using radiosurgery.

In the laboratory, his group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, Nature Genetics, and most recently in Nature, and it has received international attention with major clinical implications. Dr. Bindra is now translating this work directly into patients, in multiple phase I/II clinical trials. Most recently, Dr. Bindra discovered a novel approach to exploit DNA repair defects in cancer via DNA modification, which his group published in Science.

As an active biotech entrepreneur, he has founded six companies based on work from his laboratory, including Cybrexa Therapeutics, which is now in Phase I clinical trials. More recently, he founded Alphina Therapeutics, an early-stage biotech focused on targeting NAD metabolism in cancer, and Modifi Bio, based on DNA modification to exploit DDR defects. Under Bindra’s leadership as interim CEO, Modifi Bio was acquired by Merck and Company in the Fall of 2024.

Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University in 1998, and both his MD and PhD from the Yale School of Medicine in 2007. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center (MSKCC) in 2012.

Jean-Michel Boers, M.B.A.
US Country Managing Director, President and CEO
Boehringer Ingelheim

Jean-Michel Boers was appointed U.S. Country Managing Director, President and CEO effective August 1, 2020. Prior to his current role he was responsible for the U.S. Human Pharma business since January 2017 as President of Boehringer Ingelheim Pharmaceuticals, Inc. He steered the successful growth and development of the company’s primary and specialty care portfolio, while positioning the organization for future indication and product launches in areas of unmet medical need.

After starting his career with a German management consulting firm, Mr. Boers joined Boehringer Ingelheim in 1998 and advanced through diverse international leadership roles, including Corporate Vice President of Marketing and Sales Effectiveness at the global headquarters in Ingelheim Germany, Country Managing Director in France and Head of Human Pharma for a newly formed European regional operating unit. In July 2016, he moved to the US initially heading the Specialty Care franchise before taking leadership of the Human Pharma business in 2017.

Mr. Boers earned an M.A. in Social and Economic History from the University of Nijmegen (Netherlands) and an M.B.A. from the University of Texas.

Kat Kayser-Bricker, Ph.D.
Chief Scientific Officer,
Halda Therapeutics

Dr. Kayser-Bricker is the Chief Scientific Officer at Halda Therapeutics and serves on the board of Modifi Bio as an independent director. Kat led Halda in the invention and establishment of a novel drug modality for oncology called RIPTAC™ Therapeutics. She is responsible for scientific and corporate strategy, setting budgets, and presenting operating plans to the board of directors and founder. Kat leads the day-to-day execution of strategy, operations, IP strategy/management, and external communications.

During Kat’s years as a key scientific leader at FORMA Therapeutics, she witnessed the journey of the Series A private company to an IPO and subsequent acquisition in 2022 by Novo Nordisk for $1.1B. She held several roles of increasing responsibility with her last role being Head of Early Discovery Chemistry where she was a leader responsible for expanding the company’s portfolio. Kat successfully led several technology initiatives and programs during her time at FORMA that resulted in major collaboration milestones of >$80M.

Kat is the co-chair of the Executive Women in Bio Connecticut chapter and a member of the Humanity Talent Network (HTN) Advisory Board and Chair of the Chief Scientific Officer Collective.

Kat received her Ph.D. in organic chemistry from Yale University and her B.S. in Biochemistry from the University of Maryland, College Park.

Angela Cacace, Ph.D.
Chief Scientific Officer,
Arvinas

Dr. Angela Cacace serves as Chief Scientific Officer (CSO) at Arvinas. Prior to her role as CSO, Dr. Cacace most recently served as our Senior Vice President, Neuroscience and Platform Biology. Dr. Cacace has three decades of drug discovery experience in neuroscience and oncology research across modalities. During her time at Arvinas, Dr. Cacace has led the continuous evolution of our PROTAC Discovery Engine to employ new E3 ligases and cross the blood-brain barrier for multiple neurologic disease targets.

Previously, Dr. Cacace served as the Vice President of Biology at Fulcrum Therapeutics, where she built the biology platform, grew talented scientific teams, delivered the first development candidates, and guided the development of translational biomarkers to enable clinical development programs.

Additionally, Dr. Cacace served in positions of increasing responsibility at Bristol Myers Squibb, including as the Director of Neuroscience and Genetically Defined Diseases, where she spearheaded alternative therapeutic modalities and was a co-inventor on several development candidates. Throughout her time at Bristol Myers Squibb, she was responsible for building research-wide teams and initiatives, including the Lead Discovery and Optimization functions. While serving as a Sr. Principal Scientist in Cancer Biology at Pfizer, together with her team, she discovered a novel anti-angiogenic antibody development candidate.

Dr. Cacace received her B.S. in Biology from Fairfield University, Ph.D. in Pharmacology from Columbia University and completed her postdoctoral research in Oncology at Bristol Myers Squibb and the National Cancer Institute.

Seng H. Cheng, Ph.D.
Senior Vice President of Research and Product Development,
Alexion, AstraZeneca Rare Disease

Dr. Cheng is responsible for drug discovery, process development and clinical supply as well as clinical biomarkers and bioanalytical discovery, diagnostics, and bioinformatics, supporting the enterprise’s pipeline from target discovery through post-marketing. He also leads and manages the initiative to advance the development of genomic medicines toward clinical development.

Seng was previously Senior Vice President & Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Prior to joining Pfizer, he was Global Head of Research of Rare Diseases at Sanofi and before that, he was Group Vice President of Genetic Diseases Science at Genzyme. He has contributed to the development of several medicines for rare diseases, co-authored 283 research articles and reviews and is a named inventor on 64 issued US patents in biotechnology.

Dr. Cheng obtained his BSc and PhD degrees in Biochemistry at the University of London and trained as a postdoctoral fellow in the field of tumor biology at the National Institute of Medical Research, U.K.

Paul Fonteyne, M.B.A.
Executive in Residence,
Canaan

Paul is the retired Chairman and CEO of Boehringer Ingelheim USA. He was with BI for 15 years in leadership roles both in the US and globally. From November 2011, he was President and CEO of Boehringer Ingelheim USA, and subsequently Chairman (retired 1/1/19). During this time, he led teams that grew sales and earnings several fold and participated in acquisitions and divestitures that led to a significantly greater focus on the US portfolio of companies in two main segments of Animal Health and Human Pharmaceuticals. During his 30+ years in the pharmaceutical industry, Paul also held commercial leadership roles at Merck and Abbott Laboratories.

Paul has served on the board of PhRMA, and chaired the National Pharmaceutical Council. Prior board experience includes ResTORbio Inc (reverse merger with Adicet Bio), AMAG (sale to Apollo backed Covis), and Covetrus (animal health company acquired by TPG and CD&R). Current public company board service  includes Amylyx (AMLX) , and Apellis (APLS), and, Ypsomed AG (YPS), as well as several private companies.

Paul now serves as an Executive in Residence to Canaan, a Venture Capital Fund dedicated to Health Care and Technology early-stage investing. He advises several companies and is actively participating as a founder in biopharma university spinouts.

Paul holds dual citizenship in the USA and Belgium. He holds a MS in Chemical Engineering from the University of Brussels and an MBA for Carnegie Mellon University.

Josh Geballe, M.B.A.
Senior Associate Provost for Entrepreneurship and Innovation, Yale University;
Managing Director, Yale Ventures

Josh Geballe is Senior Associate Provost for Entrepreneurship and Innovation at Yale University and Managing Director of Yale Ventures. He is responsible for a wide range of services for students, faculty and the broader New Haven community to help launch new startups and provide training in entrepreneurship and innovation. Additional services include providing streamlined access to Yale intellectual property and sponsored research with Yale scholars, establishing partnerships to expand the impact of Yale discoveries, and growing the New Haven startup ecosystem.

Prior to joining Yale Ventures in 2022 Josh served as Chief Operating Officer for the State of Connecticut under Governor Ned Lamont. With responsibility for all executive branch agencies covering 30,000 employees he led successful initiatives to modernize state operations and expand the use of technology to improve services and reduce cost. In addition he led the state’s response to the COVID-19 pandemic, establishing nationally recognized programs for testing, contact tracing, nursing home protection, safe school operations and vaccination.

Prior to his three years in public service Josh spent his career in the technology industry, most recently as CEO of Core Informatics, a venture-backed scientific software company that was acquired by Thermo Fisher Scientific where he went on to serve as Vice President and General Manager of Digital Science. Previously he spent 11 years at IBM in a variety of international executive roles.

Josh holds an MBA from the Yale School of Management and a BA from Yale University.

Jennifer Good
Co-Founder, President, & Chief Executive Officer, Trevi Therapeutics

Jennifer Good is the co-founder, President, CEO, and a member of the Board of Directors of Trevi Therapeutics, roles she has held since founding the company in 2011. Trevi (Nasdaq: TRVI), is a clinical-stage biopharmaceutical company developing an investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Company recently reported positive Phase 2 data and is now preparing to initiate Phase 3 trials. Jennifer also serves on the board of Rhythm Pharmaceuticals, a publicly traded global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases. Jennifer has been on the Rhythm board since 2019 and is a member of their Audit Committee. Jennifer also serves on the Bio board nationally, is the Chair of the New Haven Chamber of Commerce Bioscience Collaborative and has also been a long-time board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy organization focused on advancing treatments for Friedreich’s Ataxia, a rare pediatric neuromuscular disorder. Before founding Trevi, Jennifer was the CEO of Penwest Pharmaceuticals which was acquired by its strategic partner.

Sydney Klein
Chief Information Security Officer and Head of Enterprise IT, Bristol Myers Squibb

Sydney Klein is a seasoned technology and cybersecurity executive with more than 25 years of experience across the life sciences and financial services sectors. She is widely recognized as a thought leader for her role in building secure, resilient and innovative technology organizations at scale.

Currently, as Global Chief Information Security Officer (CISO) and Head of Enterprise IT at Bristol Myers Squibb (BMS), Sydney leads the company’s global efforts to deliver a seamless digital experience that balances innovation and security while protecting the company’s most valued information. Her responsibilities span a wide range of technology areas, including cybersecurity, cloud, infrastructure, enterprise data platforms, artificial intelligence (AI), engineering, digital workforce experience, corporate function technology, employee collaboration and productivity, and more.

A recognized leader in the advancement of AI, Sydney has championed its responsible integration across the organization, driving innovation while rigorously safeguarding data security and privacy. Under her leadership, BMS has pioneered strategic initiatives that leverage AI to enhance operational efficiency, deliver transformative business outcomes, and unlock significant productivity enhancements that empower its workforce to concentrate on the work humans do best.

In addition to her technical leadership, Sydney spearheaded the development and launch of BMS’s AIQ education program, an enterprise-wide initiative designed to empower employees with critical AI knowledge and skills. Through curated learning modules, hands-on workshops, and ongoing mentorship, AIQ has helped foster a culture of digital literacy and responsible AI adoption throughout the company, positioning BMS and its workforce at the forefront of pharma’s AI transformation.

Prior to joining BMS, Sydney served as Vice President of Cyber at Capital One Financial, where she developed, launched, and scaled a range of high-impact enterprise cybersecurity and data programs over nearly two decades. Her work helped mature critical capabilities across areas such as data management, cybersecurity operations, and cyber incident reporting, several of which became industry benchmarks.

Sydney has been an active member of Global Inclusion Councils, where she has guided the company’s inclusion strategy to enhance business results. She is a sought-after speaker and thought leader, having spoken at numerous events, including the Wall Street Journal Pro Cybersecurity Forum, the Reuters Momentum AI Conference, and the Google Health Sector Security and Resilience Symposium. Sydney has been honored with several awards, including the New Power Women of D.C. in 2017, Top 100 Women in Business in 2022, Top 10 CISOs in 2022 and 2023, Top 100 Women in Cyber 2024, and as a New York CISO ORBIE finalist in 2025. She also participated in a Congressional Black Caucus Foundation “Braintrust” summit that focused on using AI to address care disparities in 2025.

Raja Mangipudy, Ph.D.
Senior Vice President, Global Head of Drug Safety Research and Development, Groton Site Director,
Pfizer

Raja Mangipudy is responsible for all aspects of non-clinical safety for small molecules, large molecules, vaccines and animal care and welfare across all therapeutic areas and sites.

Prior to joining Pfizer, Raja was Vice-President of Nonclinical Safety Evaluation and Global Veterinary Sciences at Bristol-Myers Squibb (BMS). He also served as Site Head of the company’s nonclinical safety facilities at its New Brunswick, New Jersey, location which is a major hub for BMS. Raja was responsible for global nonclinical safety evaluation across modalities and therapeutic areas including Cardiovascular, Metabolic, Oncology, Immunoscience, Neuroscience, Fibrosis and Virology.

He earned his Ph.D. at Northeast Louisiana University (now University of Louisiana Monroe) and is a Diplomate of the American Board of Toxicology. Prior to BMS, Raja held positions at Merck, Sanofi, Pharmacia, Upjohn and, for a brief time at the beginning of his career, served as part of the Pfizer sales force in India.

J. Dormer Stephen, J.D.
Partner,
Shipman & Goodwin, LLP

Dormer Stephen is Co-Chair of Shipman & Goodwin’s Business and Finance Practice Group.

Dormer handles venture capital and private equity and debt transactions, mergers and acquisitions and general corporate matters. His practice involves the representation of Fortune 500 companies, private equity funds, emerging companies and investment banks in structuring, negotiating and documenting seed through later stage equity and debt investments, mezzanine financings, syndicated credit facilities, mergers, acquisitions and joint ventures, buyouts, rollup strategies, intellectual property transactions, work-outs and financial restructurings and general corporate matters. Constituent companies are in a broad range of industries including financial services, insurance, life sciences, media, software and telecommunications. He also represents public and private clients in an “outside general counsel” capacity. Roles include counseling on strategic initiatives (such as joint ventures, joint development projects and intellectual property licensing and collaboration), commercial contract matters (such as distribution and supply agreements, license agreements and employment agreements) and other general corporate matters (such as employment and severance matters, equity incentive plans, corporate governance, real estate matters and insurance matters). As a member of the firm’s Opportunity Zones team, Dormer advises clients on various aspects of the Qualified Opportunity Zones program.

Prior to joining Shipman & Goodwin, Dormer was a Partner in the Corporate Department of Dewey & LeBoeuf LLP.

Matt Storeygard, M.B.A.
Senior Managing Director, Venture Capital Investments
CT Innovations (CI)

Matt Storeygard is a Senior Managing Director on the Venture Team at Connecticut Innovations and leads the Bio/Healthcare team.  At CI, he is responsible for sourcing and evaluating investment opportunities, structuring new investments and supporting the growth and success of portfolio companies post-investment.  He leads much of CI’s digital health investing activities.  He sits on the Board of Upswing Health, Inbox Health, Nest Collaborative, and Hubbub, and is a Board Observer on 5 additional Companies including Vita Health, Intellihealth, and ReferWell. Prior to CI, Matt’s experience includes five years at Cross Sector Consulting, where he provided strategic consulting services including planning, financial analyses, competitive analyses and implementation strategies for a variety of clients, including health care, education, community development finance and workforce organizations. Previously, he worked at the Urban Institute, where he developed predictive models to analyze the effects of health policy legislation.

Matt received his B.A. in Economics at Haverford College and an M.B.A.in Finance and Strategy at Yale School of Management.

Mike Stow, M.B.A.
Vice President of Global Marketing for Surgical Robotics
Medtronic

Mike Stow is an accomplished business leader with over 15 years of experience in medical technologies and leadership roles across marketing, strategy, and general management. He is passionate about solving clinical needs through innovation and has commercialized over 20 new technologies that positively impact millions of patients every year.
Mike’s current role is Vice President of Global Marketing at Medtronic. He is responsible for the launch of Medtronic’s new surgical robotics platform which he has taken from pre-market to over 20 countries. He is also an executive sponsor of Medtronic’s Young Professionals Connecticut chapter and actively involved in Medtronic’s Connecticut State Steering Committee.
Prior to his current role, Mike was with Hologic where he led their global Breast Health business and introduced the technology that now screens the majority of women in the US for breast cancer. He has experience across medical devices, surgical implants, surgical robotics, medical imaging, software and artificial intelligence.

Prior to Hologic, he held a variety of roles with Covidien/Medtronic in Norwalk and North Haven, Stanley Tools in New Britain, and as a design engineer for a small manufacturing company in Guilford, CT. Having lived and worked in Connecticut for over 20 years, Mike is passionate about improving the business environment for life sciences and related industries in the state.

Mike received an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Carnegie Mellon University. He has been a guest lecturer at Cornell and Quinnipiac and sponsored and judged the healthcare case competition at Yale.

Carter Winstanley
Principal,
Winstanley Enterprises

Carter Winstanley, a founder of Winstanley Enterprises, has 31 years of real estate development experience. He has developed a wide range of commercial real estate product types, with a particular expertise in the lab/biotech/technology space. Since the late 1990s, Mr. Winstanley has acquired and redeveloped over 4 million square feet of commercial real estate worth approximately $550 million. In New Haven, CT alone, Mr. Winstanley has acquired and redeveloped over 1.8 million square feet of commercial real estate.

Notable recent projects include the construction of a 14 story, 513,000 square foot Class A, LEED Platinum life sciences building in New Haven that is 100% leased to Yale University and Alexion Pharmaceuticals (the rare disease division of Astra Zeneca), the development of a neighboring 525,000 square foot Class A life sciences building that will be anchored by Arvinas and Yale University, and the multi-year redevelopment initiative of the former Winchester Arms Facility in the Science Park neighborhood in New Haven CT.

Mr. Winstanley has also worked with universities across the country, including Boston University, the University of Massachusetts, the University of Connecticut, and New York University on similar lab incubator programs. He has also developed telecom/data centers for FT Interactive Data Corp., Conversant Communications and AT&T Corp. Mr. Winstanley holds a B.A. from Colgate University.